• 3M Drug Delivery Systems Announces Expansion of MDI Facility in Loughborough, UK

    May 05, 2014

    • Investment adding 20% capacity, supporting future growth

      ST. PAUL, Minn. – May 5, 2014 –3M Drug Delivery Systems Division is making a significant investment to improve and expand its pressurized metered dose inhalation (MDI) facility in Loughborough, U.K. The investment, which will increase site capacity by more than twenty (20) percent, comes two years after the company expanded the capacity of its MDI facility in Northridge, California, and marks 3M’s continued commitment to providing state-of-the-art capabilities with a global reach for its customers.

      The Loughborough investment will enable 3M to support growth in production for its existing commercial programs as well as newly committed developments. It will also bring the company extra capacity to meet future needs of branded and generic MDI markets.

      “Since developing the first MDI almost 60 years ago, 3M has continued pioneering in inhalation drug delivery, and this expansion of our facilities will allow us to maintain that leadership,” said Marcello Napol, Vice President Inhalation Drug Delivery, 3M Drug Delivery Systems.

      3M’s contributions to the field over the past decades have continually evolved the MDI development and manufacturing process from start to finish building a position as experts at commercializing inhalation innovation.

      Additional recent investments by the company have supported the development and manufacturing of the 3M™ Integrated Dose by Dose Counter, as well as the development of the 3M™ Nasal MDI. At the Northridge facility, the 2012 expansion added a pressure fill line to complement the existing cold fill capabilities. The company now has multiple strategically located global MDI filling sites, and experience manufacturing products for distribution in more than 60 countries worldwide.

      For more information, visit 3M.com/dds.